A Dutch study in the New England Journal of Medicine found bardoxolone methyl was not effective in reducing the odds of cardiovascular death or end-stage renal disease in type 2 diabetes patients with stage 4 chronic kidney disease. Researchers examined 2,185 participants at a median follow-up of nine months and found more patients in the intervention arm were either hospitalized for heart failure or had died of the condition than in the placebo group.

Related Summaries